The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to pomalidomide–dexamethasone in relapsed and refractory multiple myeloma. Here, we report a prespecified updated overall survival analysis at 24 months after the primary analysis. Methods In this randomised, multicentre, open-label, phase 3 study adult patients (aged ≥18 years) with relapsed...Continue Reading